Additional file 1 of Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer

Additional file 1: Table S1. Clinical characteristics and molecular biomarkers at baseline in all enrolled patients. Table S2. Clinical characteristics and molecular biomarkers in patients with paired samples at baseline and after two treatment cycles. Table S3. The individual gene mutation list of all samples in this study. Table S4. Univariate COX analysis of biomarkers at baseline. Table S5. Gene mutations at baseline correlated with clinical outcomes of ICIs plus chemotherapy. Table S6. Comparison of clinical characteristics between patients with bITH-up and those with bITH-stable or down.